IL-2 was first developed as single-agent therapy for metastatic melanoma, kidney cancer, and non-Hodgkin lymphoma, where it shows some benefit in eliciting anti-tumor immune responses (50% tumor reduction in 15–20% of patients), presumably by activating T lymphocytes [60, 61]. The gene discussed is IL2; the disease is neoplasm.